Abstract:Abstract SETDB1 is characterized as an important epigenetic regulator in many different cancers and involved in transcriptional silencing of many different processes and pathways. It is often overexpressed in many different cancers including colon, melanoma, breast and pancreatic cancers and its high expression is correlated with worse patient outcome. Often associated with repressing complexes such as HUSH and KAP1/KRAB, it has been shown to repress many different genes such as p53 and p21 through histone H3K9 methylation. In addition, it has been implicated in regulating transposable elements (TEs), primarily of the LTR types as well as SINEs and LINEs. Activation of TEs is key to induction of anti-viral response genes such as the type I interferon pathway and immune-stimulated genes (ISGs) which in turn promote innate immune response against the tumor. Here, we show that SETDB1 promotes tumor growth in endometrial cancer possibly through establishing an immune evasion from the innate immune system. Mice subcutaneously injected with SETDB1 depleted endometrial cancer cells show prolonged survival time and reduced tumorigenesis. In NSG mice, we demonstrate that subcutaneously injected endometrial cancer cell, ISHIKAWA, shows both increased penetration and recruitment of macrophages in the tumor when SETDB1 is knocked out. Our macrophage-cancer cells co-culture in-vitro assay suggests that macrophages induce greater killing in SETDB1-/- cells when stimulated into M1 phenotype more so than in WT cancer cells. Further, tumor IHC analysis shows greater proliferation capacity for control tumor relative to SETDB1-/- as evident by greater mitotic figures per unit area and Ki67 staining score. We further show that cytokines such as CCL5 and CXCL9 (previously reported for their positive correlation with T-cell infiltration in tumor) are significantly upregulated in SETDB1 knockout tumors relative to non-targeting control tumors (NT) as well as in cell lines. Endometrial cancer TCGA data show significant negative correlation between SETDB1 and markers of T-cell infiltration such as CD8A and IFNG as well as cytokines CCL5 and CXCL9. Overall, these findings show important implication of SETDB1 in macrophage recruitment and macrophage-mediated killing of cancer cells in addition to its role in promoting tumor cells proliferation. Citation Format: Kiarash Salari, Matthew Wells, Eleanor R. Johnson, Tianyue Li, Jiaqing Hao, Bing Li, Shujie Yang. Understanding SETDB1-mediated tumor immune evasion mechanism in endometrial cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 675.

The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway

TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

Tumor Immune Checkpoints and Their Associated Inhibitors

E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells

SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors

The correlation between TRIM28 expression and immune checkpoints in CRPC

PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity

SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy

The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated antitumor immunity

Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity

Abstract 675: Understanding SETDB1-mediated tumor immune evasion mechanism in endometrial cancer

TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation

Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy

Targeting JMJD1C to selectively disrupt tumor T reg cell fitness enhances antitumor immunity

Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity

MP16-13 SETD2-MEDIATED LOSS OF MIR-339 PROMOTES TUMOR PD-L1 EXPRESSION AND ATTENUATES ANTITUMOR IMMUNITY IN RENAL CELL CARCINOMA

PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.

Tumor-intrinsic RGS1 Potentiates Checkpoint Blockade Response Via ATF3-IFNGR1 Axis